Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model

Journal of Critical Care

Volumn 29, Issue 1, 2014, Pages 184.e9-184.e13

  Alamili, Mahdi ^a   Bendtzen, Klaus ^b   Lykkesfeldt, Jens ^c   Rosenberg, Jacob ^a   Gögenur, Ismail ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endotoxemia; Human; Inflammation; Melatonin; Oxidative damage; Oxidative stress; Sepsis

Indexed keywords

ASCORBIC ACID; CYTOKINE; DEHYDROASCORBIC ACID; ENDOTOXIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; M 5250; MALONALDEHYDE; MELATONIN; PLACEBO; PROTEIN YKL 40; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPERIMENTAL ENDOTOXEMIA; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL;

ENDOTOXEMIA; HUMAN; INFLAMMATION; MELATONIN; OXIDATIVE DAMAGE; OXIDATIVE STRESS; SEPSIS;

ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; HUMANS; INFLAMMATION MEDIATORS; MALE; MALONDIALDEHYDE; MELATONIN; MODELS, BIOLOGICAL; OXIDATIVE STRESS; YOUNG ADULT;

EID: 85055464242     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.09.006     Document Type: Article

References (51)

1. Hodgin K.E., Moss M. The epidemiology of sepsis. Cur Pharm Des 2008, 14:1833-1839.
2. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
3. Padkin A., Goldfrad C., Brady A.R., et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales and Northern England. Crit Care Med 2003, 31:2332-2338.
4. Dombrovsky V.Y., Martin A.A., Sunderram J., et al. Facing the challenge: decreasing case fatality rates in severe sepsis despite increasing hospitalizations. Crit Care Med 2005, 33:2555-2562.
5. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
6. Stehle J.H., Saade A., Rawashdeh O., et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011, 51:17-43.
7. Hardeland R., Madrid J.A., Tan D.X., et al. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012, 52:139-166.
8. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011, 51:1-16.
9. Mauriz J.L., Collado P.S., Veneroso C., et al. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013, 54:1-14.
10. Reiter R.J., Tan D.X., Qi W., et al. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000, 9:160-171.
11. Reiter R.J., Tan D.X., Manchester L.C., et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001, 34:237-256.
12. Sánchez-Barceló E.J., Mediavilla M.D., Tan D.X., et al. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010, 17:2070-2095.
13. Sewerynek E., Abe M., Reiter R.J., et al. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phrenobarbital-treated animals. J Cell Biochem 1995, 58:436-444.
14. Shi D., Xiao X., Wang J., et al. Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-kB, c/EBPB, and p300 signaling. J Pineal Res 2012, 53:154-165.
15. Wu C.C., Chiao C.W., Hsiao G., et al. Melatonin prevents endotoxin-induced circulatory failure in rats. J Pineal Res 2001, 30:147-156.
16. Xia M.Z., Liang Y.L., Wang H., et al. Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells. J Pineal Res 2012, 53:325-334.
17. Srinivasan V., Pandi-Perumal S.R., Spence D.W., et al. Melatonin in septic shock: some recent concepts. J Crit Care 2010, 25:e1-e6.
18. Carrillo-Vico A., Guerrero J.M., Lardone P.J., et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27:189-200.
19. Cuzzocrea S., Thiemermann C., Salvemini D. Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr Med Chem 2004, 11:1147-1162.
20. Cuzzocrea S., Reiter R.J. Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2002, 2:153-165.
21. Gitto E., Karbownik M., Reiter R.J., et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001, 50:756-760.
22. Escames G., Acuña-Castroviejo D., López L.C., et al. Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. J Pharm Pharmacol 2006, 58:1153-1165.
23. Andreasen A.S., Krabbe K.S., Krogh-Madsen R., et al. Human endotoxemia as a model of systemic inflammation. Curr Med Chem 2008, 15:1697-1705.
24. Kücükakin B., Klein M., Lykkesfeldt J., et al. No effect of melatonin on oxidative stress after laparoscopic cholecystectomy: a randomized placebo-controlled trial. Acta Anaesthesiol Scand 2010, 54:1121-1127.
25. Kücükakin B., Wilhelmsen M., Lykkesfeldt J., et al. No effect of melatonin to modify surgical-stress response after major vascular surgery: a randomised placebo-controlled trial. Eur J Vasc Endovasc Surg 2010, 40:461-467.
26. Sakaguchi S., Furusawa S. Oxidative stress and septic shock: metabolic aspects of oxygen-derived free radicals generated in the liver during endotoxemia. FEMS Immunol Med Microbiol 2006, 47:167-177.
27. Hallwell B. Free radical, antioxidants and human disease: curiosity, cause, or consequence?. Lancet 1999, 344:721-724.
28. Mishra V., Baines M., Wenstone R., et al. Markers of oxidative damage, antioxidant status and clinical outcome in critically ill patients. Ann Clin Biochem 2005, 42:269-276.
29. Batra S., Kumar R., Kapoor A.K., et al. Alterations in antioxidant status during neonatal sepsis. Ann Trop Paediatr 2000, 20:27-33.
30. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118:503-508.
31. Opal S.M., DePalo V.A. Anti-inflammatory cytokines. Chest 2000, 117:1162-1172.
32. Reiter R.J., Tan D.X., Mayo J.C., et al. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003, 50:1129-1146.
33. Korkmaz A., Reiter R.J., Topal T., et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009, 15:43-50.
34. Barlow-Walden L.R., Reiter R.J., Abe M., et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995, 26:497-502.
35. Pablos M.I., Reiter R.J., Ortiz G.G., et al. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int 1998, 32:69-75.
36. Rodriguez C., Mayo J.C., Sainz R.M., et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004, 36:1-9.
37. Fulia F., Gitto E., Cuzzocrea S., et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res 2001, 31:343-349.
38. Gitto E., Romeo C., Reiter R.J., et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004, 39:184-189.
39. Gitto E., Reiter R.J., Amodio A., et al. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 2004, 36:250-255.
40. Gitto E., Reiter R.J., Cordaro S.P., et al. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol 2004, 21:209-216.
41. Alamili M, Klein M, Lykkesfeldt J, et al. Circadian variation in the response to experimental endotoxaemia and modulatory effects of exogenous melatonin. Chronobiol Int 2013. (in press).
42. Gitto E., Pelligrino S., Gitto P., et al. Oxidative stress of the newborn in the pre- and post-natal period and the clinical utility of melatonin. J Pineal Res 2009, 46:128-139.
43. Sokullu O., Sanioǧlu S., Kurç E., et al. Does the circadian rhythm of melatonin affect ischemia-reperfusion injury after coronary artery bypass grafting?. Heart Surg Forum 2009, 12:E95-E99.
44. Tan D.X., Manchester L.C., Terron M.P., et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J Pineal Res 2007, 42:28-42.
45. Lane E.A., Moss H.B. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985, 61:1214-1216.
46. Hara M., Iigo M., Ohtani-Kaneko R., et al. Administration of melatonin and related indoles prevents exercise-induced cellular oxidative changes in rats. Biol Signals 1997, 6:90-100.
47. Maharaj D.S., Anoopkumar-Dukie S., Glass B.D., et al. The identification of the UV degradants of melatonin and their ability to scavenge free radicals. J Pineal Res 2002, 32:257-261.
48. Ressmeyer A.R., Mayo J.C., Zelosko V., et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003, 8:205-213.
49. Galano A., Tan D.X., Reiter R.J. The free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013, 54:245-257.
50. Mundigler G., Delle-Karth G., Koreny M., et al. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med 2002, 30:536-540.
51. da Silveira Cruz-Machado S., Carvalho-Sousa C.E., Tamura E.K., et al. TLR4 and CD14 receptors expressed in rat pineal gland trigger NFKB pathway. J Pineal Res 2010, 49:183-192.